Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hansson Goran K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.
Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 1997;349:1436–42.
Allana GM, Garrisona S, McCormack J. Comparison of cardiovascular disease risk calculators. Curr Opin Lipidol. 2014;25(4):254–65.
Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.
Loprinzi PD, Addoh O. Predictive validity of the American college of cardiology/American heart association pooled cohort equations in predicting all-cause and cardiovascular disease specific mortality in a national prospective cohort study of adults in the United States. Mayo Clin Proc. 2016;91(6):763–9.
Sara JD, Widmer RJ, Matsuzawa Y, et al. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv. 2015;8(11):1445–53.
Borges FK, Stella SF, Souza JF, et al. Serial analyses of C-reactive protein and myeloperoxidase in acute coronary syndrome. Clin Cardiol. 2009;32(11):58–62.
Luc G, Bard JM, Juhan-Vague I, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol. 2003;23(7):1255–61.
Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127–37.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascularevents in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.
Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med. 1990;7:147–59.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–72.
Su D, Li Z, Li X, Chen Y, et al. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediat Inflamm. 2013;2013:726178.
Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.
Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22:147–51.
Mancini GB, Hartigan PM, Shaw LJ, et al. Predicting outcome in the COURAGE trial (clinical outcomes utilizing revascularization and aggressive drug evaluation). JACC. 2014;7(2):195–201.
Hou H, Wang C, Sun F, Zhao L, Dun A, Sun Z. Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis. Inflamm Res. 2015;64(9):707–20.
Caselli C, De Graaf MA, Lorenzoni V, et al. HDL cholesterol, leptin and interleukin-6 predict high risk coronary anatomy assessed by CT angiography in patients with stable chest pain. Atherosclerosis. 2015;241(1):55–61.
Hudzik B, Szkodzinski J, Romanowski W, et al. Serum interleukin-6 concentration reflects the extent of asymptomatic left ventricular dysfunction and predicts progression to heart failure in patients with stable coronary artery disease. Cytokine. 2011;54(3):266–71.
Shirai T, Nafarewicz RR, Wallis BB. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J Exp Med. 2016;213:337–54.
Kuller LH, Tracey RP, Shaten J, MRFIT Research Group, et al. Relation of C-reactive protein and coronary heart disease in MRFIT nested case-control study. Am J Epidemiol. 1996;144:537–47.
Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–809.
Burgess S, Kaptoge S, Di Angelantonio E, et al. Association between C-reactive protein and coronary heart disease: mendelian randomization analysis based on individual participant data. BMJ. 2011;342:548.
Niu W, Liu Y, Qi Y, Wu Z, Zhu D, et al. Association of interleukin-6 circulating levels with coronary artery disease: a metanalysis implementing mendelian randomization approach. Int J Cardiol. 2012;157(2):243–52.
Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessels. 2008;23(4):249–56.
Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheumatol. 2008;58:2968–80.
Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286(17):2107–13.
Magadle R, Weiner P, Beckerman M, Berar-Yanay N. C-reactive protein as a marker for active coronary artery disease in patients with chest pain in the emergency room. Clin Cardiol. 2002;25(10):456–60.